Pfizer Takes ‘Opportunistic’ Approach To Future Biosimilars

Company Sees 93% Growth In Biosimilars Business To $559m In Q2

 
• By Akriti Seth
Growth
Pfizer has seen growth in both biosimilars and sterile injectables business • Source: Alamy

More from Biosimilars

More from Products